The present invention relates to a pharmaceutical composition for preventing or treating lupus-related diseases comprising a triple agonist, which activates a glucagon receptor, glucagon-like peptide-1 (GLP-1) receptor, and glucose-dependent insulinotropic polypeptide (GIP) receptor, pharmaceutically acceptable salt thereof, solvate thereof, or long-acting conjugate thereof, the pharmaceutical composition reducing the size of inflammation-caused edema, improving skin lesions, and reducing the weight and size of the spleen in a lupus disease animal model.
展开▼
